Syngene International Second Quarter 2025 Earnings: EPS Beats Expectations

Syngene International (NSE:SYNGENE) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₹8.91b (down 2.1% from 2Q 2024).
• Net income: ₹1.06b (down 8.9% from 2Q 2024).
• Profit margin: 12% (in line with 2Q 2024).
• EPS: ₹2.64 (down from ₹2.90 in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Syngene International EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India.

Performance of the Indian Life Sciences industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You still need to take note of risks, for example - Syngene International has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.